Dr. Michael Y. Lin, MD, PhD

Dr. Lin practices at Ambulatory Surgery Center of Stockton in Stockton, California.

Dr. Lin's NPI, 1972742427, was assigned on February 6, 2009. Dr. Lin graduated from WashU Medicine in 2007. Dr. Lin holds California license A106314.

Dr. Lin's primary practice is Ambulatory Surgery Center of Stockton, at 2388 North California Street, Stockton, CA 95205. The practice phone is (209) 944-9100.

Dr. Lin's primary practice is Ambulatory Surgery Center of Stockton in Stockton, California. Dr. Lin is also affiliated with Dameron Hospital. The medical group on file is SGMF Radiology. Dmand AI also links Dr. Lin to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 5 sites in all. Vendor and product names are available with a free account.

Orthopaedic surgery is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207X00000X. Dr. Lin is board certified in orthopaedic surgery by the American Board of Orthopaedic Surgery. Dr. Lin is licensed in California.

Dmand AI lists arm, wrist, hand fracture and dislocation, arthritis, bursitis, carpal tunnel syndrome, enthesopathy in arms, hand joint or tendon inflammation, hip replacement and joint arthropathy among the conditions Dr. Lin treats.

CMS data shows 2,410 Medicare services from Dr. Lin across 17 procedure codes in 2024, for 375 Medicare patients. Medicare paid $83,749 for them.

CMS counts 375 Medicare patients who saw Dr. Lin in 2024. The largest group is 65 to 74, with 166 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 1.19, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 60, with 51% women.

In 2024, Dr. Lin wrote 364 Medicare Part D claims for 197 patients. 99% of them were for generic drugs. CMS names the drug for 310 of them, across 8 drugs with 11 or more claims each, at $2,229 in total drug cost. In 2023, CMS named 403 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 2 papers to Dr. Lin. Dr. Lin's most frequent co-authors are Ranjan Gupta, MD, Givenchy W. Manzano, MD and Tahseen Mozaffar, MD.

CMS Open Payments shows 4 general payments to Dr. Lin from 4 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 100% of the total. Sanofi and Genzyme US Companies paid the most, $29.

Dr. Lin graduated from WashU Medicine in 2007.

Dr. Lin is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.